Paige vs PathAI (2026)
Paige sells AI that reads slides; PathAI sells the image management system slides are read in, with its own algorithms as research tools. Paige Prostate holds a De Novo authorization (DEN200080, 2021) as an adjunct that flags the area of a prostate biopsy most likely to contain cancer, and Paige now sells suites for prostate, breast, gastrointestinal and pan cancer work alongside the Virchow foundation models. PathAI's AISight Dx is 510(k) cleared for primary diagnosis (K243391) with four named scanners and runs partner algorithms, Paige's among them; PathAI's own algorithms are research use only in the United States. Both are changing hands: Tempus acquired Paige in August 2025, and PathAI agreed in May 2026 to be acquired by Roche.
- You want an authorization that covers the algorithm itself: Paige Prostate's De Novo flags the most suspicious area on a prostate biopsy.
- You want foundation models to build on, including the Virchow family, some of it open sourced.
- You already work in the Tempus oncology ecosystem, which now owns Paige.
- You need the platform first: AISight Dx is cleared for primary diagnosis with four named scanners.
- You want one workspace that runs PathAI's algorithms beside partner algorithms, including Paige's.
- You run MASH trials: AIM-MASH AI Assist is qualified by the EMA and, as a drug development tool, by the FDA.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Paige and PathAI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Paige | PathAI |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2016 |
| Headquarters | New York, New York, United States | Boston, Massachusetts, United States |
| Website | paige.ai | pathai.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Paige
-
Product / capability
Paige launched an AI tool that screens 505 genes directly from H and E stained pathology slides, without requiring next generation sequencing as a first step.
Source
PathAI
-
Product / capability
PathAI released version 2.21 of its AISight Dx digital pathology platform, introducing customizable case dashboards, an AI impressions widget, and expanded metadata support for bulk slide ingestion.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Computational pathology company that produced the first FDA authorized AI based digital pathology product: Paige Prostate received De Novo authorization (DEN200080) in September 2021 as an adjunct that flags the area of a digitized prostate biopsy most likely to contain cancer, used with a specified scanner and the company's FullFocus viewer.
Source: AI Health Index, September 2026
Digital pathology company selling the AISight image management system and its own AI algorithms. AISight Dx is FDA 510(k) cleared (K243391, June 2025) for primary diagnosis with four named scanners and CE-IVD marked in Europe, and is deployed at laboratories including Labcorp and MedStar Health.
Source: AI Health Index, September 2026
Questions buyers ask
How do Paige and PathAI work with the EHR?
Paige ships its own viewing and case management layer, the FDA cleared FullFocus viewer and the FullFolio image management system, as a turnkey option, and states that its applications also run inside partner digital pathology platforms, so a laboratory that already runs an image management system need not replace it.
The image management pages say AISight is interoperable with most major laboratory information systems and with Hamamatsu, Leica, Roche and Philips scanners, and that AISight Link, PathAI's open API, powers LIS integration and embeds partner algorithms in the viewer. The pages name no LIS product, no standard such as HL7 or DICOM, and no integration documentation. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Paige and PathAI priced and sold?
In Paige's case, the suites and the platform carry no list price, tier structure, per slide or per case rate, or subscription level. Evaluation runs through a trial request and commercial terms through contact with the company, and the platform has been distributed through a cloud marketplace, which can carry standard terms.
The product pages carry no license fee, per case or per slide rate, tier structure or worked example for AISight, AISight Dx, PathAI's own algorithms or the partner algorithms offered through the platform, and commercial contact runs through a demo request or a dedicated sales address. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Paige and PathAI handle patient data?
Paige's privacy policy is scoped to the company's websites and online services, and the personal information it lists is business and website contact data collected through analytics and marketing tools; it does not describe what happens to the whole slide images a laboratory processes through the Paige Platform or Alba.
The privacy notice (effective 13 February 2025), which covers PathAI's platforms, says PathAI requests only the minimum information needed and retains it only as long as necessary to provide the services or for compatible purposes, including providing additional services. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Paige and PathAI cover?
For Paige, the company sells suites for prostate, breast, gastrointestinal and pan cancer pathology to clinical pathology laboratories, and, through Tempus, reaches precision oncology programs. Paige Prostate's authorization names its setting precisely: digitized prostate biopsy images from the Philips Ultra Fast Scanner, viewed in FullFocus, as an adjunct to the pathologist's review.
With PathAI, the biomarker algorithms name their indications and supported antibody clones (PD-L1 in non-small cell lung, head and neck, melanoma and urothelial cancer; HER2, ER, PR and Ki-67 in breast), and the menu extends to ulcerative colitis and dermatopathology, but these are research use only in the United States with no validation named on the product pages. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
The two regulatory positions are different objects: Paige's De Novo covers an algorithm for one indication, and PathAI's clearance covers the image management system, not its algorithms. Paige's current site does not state the regulatory status of each suite. Both companies are under new or pending ownership, so ask how licensing and support carry over. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.